Stimulation of the erythropoietin receptor (EPO-R) or the interleukin-2 receptor (IL-2-R) by their respective ligands has been reported to activate tyrosine phosphorylation of the cytoplasmic protein, Shc. We have recently characterized a cell line, CTLL-EPO-R, that contains functional cell-surface receptors for both EPO and IL-2. Although stimulation with IL-2 or IL-15 resulted in the rapid, dose-dependent tyrosine phosphorylation of Shc, stimulation with EPO failed to activate Shc. EPO, IL-2, and IL-15 activated the tyrosine phosphorylation of the adaptor protein, Shp2, and the association of Shp2/Grb2/cytokine receptor complexes. In addition, EPO, IL-2, and IL-15 activated Raf1 and ERK2, demonstrating that the Raf1/MEK/MAP kinase pathway was activated. These results indicate that multiple biochemical pathways are capable of conferring a mitogenic signal in CTLL-EPO-R. EPO can activate the Raf1/MEK/ MAP kinase pathway via Shc-dependent or Shc-independent pathways, and Shc activation is not required for EPO-dependent cell growth in CTLL-EPO-R.

ERYTHROPOIETIN (EPO) and other hematopoietic growth factors have diverse effects on the proliferation and differentiation of blood cells. These effects are mediated through binding to specific, high-affinity cell-surface receptors. Postreceptor signal transduction pathways remain poorly understood and probably elicit both mitogenic and differentiation signals. After ligand binding, cytokine receptors activate multiple signaling cascades. For instance, a distal region (amino acids 626-763) of the interleukin-3 receptor (IL-3-R) βc chain activates Ras, resulting in c-fos and c-jun induction.1 This region is distal to a domain which associates with JAK22 and is essential for mitogenesis.3 

Activation of the Ras/Raf1/MAP kinase pathway can be accomplished via the SH2 domain containing adapter proteins, Grb2 and Shc. Grb2 is a cytoplasmic adaptor protein consisting of one SH2 domain flanked by two SH3 domains.4 Grb2 binds activated growth factor receptors5-9 and other tyrosine-phosphorylated proteins such as insulin receptor substrate-1 (IRS-1)10,11 through its SH2 domain and binds the guanine nucleotide releasing factor mammalian (m)SOS1 through its SH3 domains.5-11 This leads to translocation of mSOS1 to Ras, which resides in the plasma membrane, and results in increased exchange of GDP for GTP on Ras.

Shc12 is a modular protein containing both an amino terminal phosphotyrosine binding domain (PTB)13 and a carboxy terminal SH2-domain.14 It is tyrosine phosphorylated at Y317 in response to multiple growth factors.15 Overexpression of Shc can lead to fibroblast transformation12 or neuronal differentiation of PC12 cells.16,17 The SH2 domain of Grb2 binds tyrosine-phosphorylated Shc, suggesting that a Grb2-Shc complex may be involved in receptor-mediated Ras activation. Previous studies of the EPO-R have shown that Grb2 can either bind directly or indirectly via Shc to the tyrosine-phosphorylated EPO-R.18-21 

Recent data have demonstrated a third mechanism by which an activated growth factor receptor can couple Grb2 to the Ras pathway. The tyrosine-phosphatase Shp222-25 can function as an adaptor coupling the platelet-derived growth factor receptor (PDGF-R) activation to Grb2 binding.26-28 Like Shc, when Shp2 is tyrosine phosphorylated, the SH2 domain of Grb2 can associate with Shp2. Therefore, Grb2 can associate directly with activated receptors or can associate indirectly via interaction with Shc or Shp2. A physical interaction between the EPO-R and Shp2 has been observed,29 suggesting that this mechanism is important in EPO-R signal transduction. Mutation of EPO-R Y425 was found to perturb Shp2 association and expression of EPO-R Y425F in DA-3 cells resulted in decreased EPO-dependent proliferation.30 

In the current study, we have compared IL-2 and EPO signal transduction mechanisms within the same cellular background (CTLL-EPO-R). The EPO-R was ectopically expressed in CTLL cells, generating a cell line that displayed IL-2-, IL-15-, and EPO-dependent proliferation.31,32 We have previously used these cells to show that IL-2 and EPO activate distinct JAK kinase family members.32 IL-2 does activate Shc as previously described,33-36 but surprisingly, EPO fails to activate Shc in these cells. We conclude that EPO activation of Shc is not required for mitogenesis and that the EPO-R can use alternate pathways to activate the Ras/Raf1/MAP kinase pathway. The EPO-R can couple to Ras in these cells either through direct Grb2 binding or via the adaptor protein, Shp2.

Cells and cell culture.Ba/F337 and DA-3 cells38 (generously provided by J. Ihle, Memphis, TN) were maintained in RPMI 1640 medium supplemented with 10%(vol/vol) fetal calf serum (FCS) and with 5% conditioned medium from WEHI 3B cells (IL-3 medium). CTLL-2 cells39 were maintained in RPMI 1640 medium supplemented with 10% FCS and 2 U of murine recombinant IL-2 (Boehringer Mannheim, Indianapolis, IN) per milliliter (IL-2 medium). HCD-57 cells40 were cultured in IMDM supplemented with 30% FCS and 0.1 U/mL of human recombinant EPO (Kirin Brewery, Tokyo, Japan) per mL.

DNA transfection.Ba/F3-EPO-R cells and DA-3-EPO-R cells were transfected by electroporation with pLXSN-EPO-R cDNA. Selection with G418 (1.0 mg/mL) in IL-3 medium was initiated 48 hours after electroporation. Similarly, CTLL-EPO-R cells31 were generated by co-electroporation with pXM-EPO-R cDNA and pSV2-neo. Selection was performed with G418 (1.0 mg/mL) in IL-2 medium. Subclones were cultured in RPMI 1640 medium supplemented with 10% FCS and 0.5 U/mL murine recombinant EPO per milliliter.

Analysis of Shc activation and identification of associated proteins.For starvation assays, cell lines were incubated in RPMI 1640/10% FCS (no supplemental growth factor) for a 4-hour period and then stimulated for various periods with either no factor, IL-2, IL-3 (Kirin Brewery), IL-4 (Genzyme, Cambridge, MA), IL-15 (generously provided by Immunex Corp, Seattle, WA), or EPO (Kirin Brewer). Cell lysates were prepared in 50 mmol/L Tris-HCl (pH 8.0) 150 mmol/L NaCl, 1.0% Triton X-100 plus phosphatase and protease inhibitors as previously described.41 Immunoprecipitations were performed with either a Shc polyclonal antibody (Transduction Laboratories, Lexington, KY), a Grb2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), an Shp2 monoclonal antibody (MoAb) (Transduction Laboratories), or an anti-N-terminal EPO-R polyclonal antibody as previously described.41 Immune complexes were isolated with Protein A-Sepharose (Sigma, St Louis, MO), washed three times with 50 mmol/L Tris HCl (pH 8.0), 150 mmol/L NaCl, 0.1% Triton X-100, 10 mmol/L Na2P2O7 , 10 mmol/L NaF, 5 mmol/L EDTA, 1 mmol/L Na3VO4 , and prepared for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously.41 

Glutathione-S-transferase (GST) fusion proteins expressing the SH2 domains of Grb2, Shp2, and Shc were produced in bacteria as described.42 For in vitro binding analysis, 5 μg of each fusion protein was incubated with 2 mg of lysate from CTLL-EPO-R cells stimulated with no factor, 50 U/mL IL-2, or 50 U/mL EPO. The glutathione-Sepharose beads were washed and bound proteins were resolved via SDS-PAGE as described above.

After electrophoretic transfer of proteins to nitrocellulose, the membrane was blocked and incubated with the antiphosphotyrosine MoAb 4G10, washed in 50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl 0.1% Triton X-100 (TBST), followed by horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG (Amersham, Arlington Heights, IL), followed by washing in TBST. Alternatively, following blocking, the membrane was incubated with HRP-conjugated antiphosphotyrosine monoclonal antibody RC20 (Transduction Laboratories). After enhanced chemiluminescence detection, the membrane was stripped by incubation in 62.5 mmol/L Tris-HCl (pH 6.8), 2% (wt/vol) SDS, 100 mmol/L β-mercaptoethanol for 1 hour at 55°C. Membranes were blocked and reprobed with either an Shc polyclonal antibody, Grb2 MoAb (Transduction Laboratories) or an Shp2 MoAb and washed. Incubations were performed with the relevant secondary reagent, either HRP-Protein A (Amersham, Arlington Heights, IL) or HRP-sheep anti-mouse IgG and the membrane was washed before enhanced chemiluminescence detection.

Analysis of Raf1 and MAP kinase pathway activation.CTLL-EPO-R cells were depleted of factor in RPMI/1% bovine serum albumin, for an 8-hour period. Cells were stimulated with various growth factors. After lysis, an immunoprecipitation was performed with an anti-Raf1 antibody.43 The immunoprecipitations were washed with 40 mmol/L TrisHCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, and then 25 mmol/L HEPES (pH 7.4), 1 mmol/L dithiothreitol, 10 mmol/L MgCl2 , 2 mmol/L MnCl2 . Forty microliters of kinase buffer was added in the presence of 15 μmol/L adenosine triphosphate (ATP), 10 μCi 32P-γ-ATP, and 0.1 μg kinase inactive purified MEK1 (kindly provided by Dr T. Sturgell, University of Virginia, Charlottesville) and reactions were allowed to proceed 30 minutes at room temperature. The reaction was stopped with SDS-PAGE loading buffer, samples were boiled, resolved by SDS-PAGE, and transferred to nitrocellulose. The phosphorylation of MEK1 was quantitated by phosphorimager analysis and the amount of Raf1 protein in each lane was quantitated by a protein immunoblot and densitometry analysis.

For analysis of ERK1/2 activation, immunoprecipitations were performed from cytokine-stimulated lysates using an anti-ERK1 antibody (Santa Cruz Biotechnology) or an anti-ERK2 antibody (Santa Cruz Biotechnology). Immunoprecipitates were washed twice in 50 mmol/L TrisHCl (pH 8.0), 150 mmol/L NaCl, 0.1% Triton X-100, 0.1 mmol/L Na3VO4 , and once in 5 mmol/L HEPES, 10 mmol/L MgCl2 , 0.1 mmol/L Na3VO4 . Kinase reactions were performed in 50 μL of 5 mmol/L HEPES, 10 mmol/L MgCl2 , 0.1 mmol/L Na3VO4 , 5 μg myelin basic protein, 1 μmol/L unlabeled ATP, 10 μCi of 32P-γ-ATP for 15 minutes at 30°C. The reaction was stopped with SDS-PAGE loading buffer, samples were boiled, resolved by SDS-PAGE, and transferred to nitrocellulose. The phosphorylation of MBP was quantitated by phosphorimager analysis and the amount of ERK2 protein in each lane was quantitated by a protein immunoblot and densitometry analysis.

EPO-induced mitogenesis does not require Shc activation in CTLL-EPO-R cells.Previous studies showed that Shc activation was observed after stimulation of EPO-dependent hematopoietic cells.18-21,41 To further test for EPO-induced Shc tyrosine phosphorylation, we examined several EPO-dependent hematopoietic cell lines (Fig 1). The 52- and 46-kD Shc proteins were tyrosine phosphorylated by IL-3 in Ba/F3 (Fig 1, lane 2), IL-3 or EPO in BaF/3-EPO-R (Fig 1, lanes 5 and 6) and in DA-3-EPO-R (see Fig 4) transfectants as previously reported.18,19,41 HCD-57,40 a murine cell line expressing EPO-R, also activated Shc tyrosine phosphorylation upon EPO stimulation (Fig 1, lane 8). IL-2 activated Shc in CTLL (Fig 1, lane 10) CTLL-EPO-R (Fig 1, lane 13) cells. Surprisingly, EPO-dependent Shc phosphorylation was not observed after stimulation of CTLL-EPO-R-cells (Fig 1, lane 14). Similar amounts of Shc are expressed in the various cells lines as revealed by reprobing the blot for Shc (Fig 1, Shc immunoblot). Tyrosine phosphorylation of Shc at Y317 results in the binding of the adapter protein Grb2 to Shc.15 To examine this association, the blot was reprobed for Grb2 (Fig 1, Grb2 Immunoblot). Grb2 binding correlated with tyrosine phosphorylation of Shc.

Fig. 1.

EPO fails to activate Shc tyrosine phosphorylation in CTLL-EPO-R cells. Ba/F3 (lanes 1 through 3), Ba/F3-EPO-R (lanes 4 through 6), HCD-57 (lanes 7 and 8), CTLL (lanes 9 through 11), and CTLL-EPO-R (lanes 12 through 14) cells were depleted of cytokine for 4 hours and stimulated with no factor (lanes 1, 4, 7, 9, and 12), 50 U of murine IL-3 (lanes 2 and 5), 50 U of murine IL-2 per milliliter (lanes 10 and 13), or 50 U of human EPO per milliliter (lanes 3, 6, 8, 11, and 14) for 10 minutes. After cell lysis, an immunoprecipitation was performed with an Shc polyclonal antibody. Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with HRP-conjugated antiphosphotyrosine (pTyr) MoAb RC20. The blot was then stripped and reprobed with an Shc polyclonal antibody (Shc immunoblot) or a Grb2 MoAb (Grb2 immunoblot).

Fig. 1.

EPO fails to activate Shc tyrosine phosphorylation in CTLL-EPO-R cells. Ba/F3 (lanes 1 through 3), Ba/F3-EPO-R (lanes 4 through 6), HCD-57 (lanes 7 and 8), CTLL (lanes 9 through 11), and CTLL-EPO-R (lanes 12 through 14) cells were depleted of cytokine for 4 hours and stimulated with no factor (lanes 1, 4, 7, 9, and 12), 50 U of murine IL-3 (lanes 2 and 5), 50 U of murine IL-2 per milliliter (lanes 10 and 13), or 50 U of human EPO per milliliter (lanes 3, 6, 8, 11, and 14) for 10 minutes. After cell lysis, an immunoprecipitation was performed with an Shc polyclonal antibody. Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with HRP-conjugated antiphosphotyrosine (pTyr) MoAb RC20. The blot was then stripped and reprobed with an Shc polyclonal antibody (Shc immunoblot) or a Grb2 MoAb (Grb2 immunoblot).

Close modal
Fig. 4.

EPO and IL-2 activate Grb2 association with the tyrosine phosphatase, Shp2. CTLL-EPO-R cells were depleted of cytokine for 4 hours and stimulated with no factor (lanes 1 and 6), 50 U of murine IL-2 per milliliter (lanes 2 and 7), 100 ng of murine IL-4 per milliliter (lanes 3 and 8), 100 ng of simian IL-15 per milliliter (lanes 4 and 9), or 50 U of human EPO per milliliter (lanes 5 and 10) for 10 minutes. After cell lysis, an immunoprecipitation was performed with a Grb2 polyclonal antibody (lanes 1 through 5). Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with 4G10 monoclonal antiphosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. The blot was then consecutively stripped and reprobed with an Shc polyclonal antibody (Shc immunoblot), an Shp2 MoAb (Shp2 immunoblot), and a Grb2 MoAb (Grb2 immunoblot). Lysate controls from CTLL-EPO-R cells are illustrated in lanes 6 through 10. Molecular mass standards are indicated. Ab, antibody.

Fig. 4.

EPO and IL-2 activate Grb2 association with the tyrosine phosphatase, Shp2. CTLL-EPO-R cells were depleted of cytokine for 4 hours and stimulated with no factor (lanes 1 and 6), 50 U of murine IL-2 per milliliter (lanes 2 and 7), 100 ng of murine IL-4 per milliliter (lanes 3 and 8), 100 ng of simian IL-15 per milliliter (lanes 4 and 9), or 50 U of human EPO per milliliter (lanes 5 and 10) for 10 minutes. After cell lysis, an immunoprecipitation was performed with a Grb2 polyclonal antibody (lanes 1 through 5). Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with 4G10 monoclonal antiphosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. The blot was then consecutively stripped and reprobed with an Shc polyclonal antibody (Shc immunoblot), an Shp2 MoAb (Shp2 immunoblot), and a Grb2 MoAb (Grb2 immunoblot). Lysate controls from CTLL-EPO-R cells are illustrated in lanes 6 through 10. Molecular mass standards are indicated. Ab, antibody.

Close modal

To verify the absence of EPO-dependent Shc activation in CTLL-EPO-R cells, a dose-response experiment was performed. Stimulation with increasing concentrations of IL-2 resulted in dose-dependent Shc tyrosine phosphorylation (Fig 2A, lanes 2 through 6) after a 5-minute incubation. In contrast, EPO failed to activate Shc at concentrations as high as 100 U/mL (Fig 2A, lanes 8 through 13). Equivalent amounts of Shc were immunoprecipitated with each stimulation (Fig 2A, Shc immunoblot). Grb2 was shown to bind to Shc only after stimulation in an IL-2–dependent manner (Fig 2A, Grb2 immunoblot).

Fig. 2.

Dose-dependent activation and time course of Shc tyrosine phosphorylation in CTLL-EPO-R cells. (A) CTLL-EPO-R cells were incubated in the depleted of cytokine for 8 hours and then stimulated with no added factor (lanes 1 and 7), or various concentrations of IL-2 (lanes 2 through 6) or EPO (lanes 8 through 13) for 5 minutes as shown. After cell lysis, an immunoprecipitation was conducted with anti-Shc polyclonal antibody. Western blot analysis using the monoclonal antiphosphotyrosine 4G10 antibody was performed (pTyr immunoblot). The blot was stripped and reprobed with an anti-Shc polyclonal antibody (Shc immunoblot) or an anti-Grb2 MoAb (Grb2 immunoblot). Molecular mass standards are indicated. Ab, antibody. (B) CTLL-EPO-R subclone 22 (lanes 1 through 12) and CTLL-EPO-R subclone 5 (lanes 13 and 14) were starved for 8 hours and then stimulated with no added factor (lanes 1, 7, and 13), 50 U/mL IL-2 (lanes 2 through 6), or 50 U/mL EPO (lanes 8 through 12 and 14) for various times as shown. After cell lysis, an immunoprecipitation was conducted with anti-Shc polyclonal antibody. Western blotting using the monoclonal antiphosphotyrosine 4G10 was performed (pTyr immunoblot). The blot was stripped and reprobed with an anti-Shc polyclonal antibody (Shc immunoblot) or an anti-Grb2 MoAb (Grb2 immunoblot). Molecular mass standards are indicated. Ab, antibody.

Fig. 2.

Dose-dependent activation and time course of Shc tyrosine phosphorylation in CTLL-EPO-R cells. (A) CTLL-EPO-R cells were incubated in the depleted of cytokine for 8 hours and then stimulated with no added factor (lanes 1 and 7), or various concentrations of IL-2 (lanes 2 through 6) or EPO (lanes 8 through 13) for 5 minutes as shown. After cell lysis, an immunoprecipitation was conducted with anti-Shc polyclonal antibody. Western blot analysis using the monoclonal antiphosphotyrosine 4G10 antibody was performed (pTyr immunoblot). The blot was stripped and reprobed with an anti-Shc polyclonal antibody (Shc immunoblot) or an anti-Grb2 MoAb (Grb2 immunoblot). Molecular mass standards are indicated. Ab, antibody. (B) CTLL-EPO-R subclone 22 (lanes 1 through 12) and CTLL-EPO-R subclone 5 (lanes 13 and 14) were starved for 8 hours and then stimulated with no added factor (lanes 1, 7, and 13), 50 U/mL IL-2 (lanes 2 through 6), or 50 U/mL EPO (lanes 8 through 12 and 14) for various times as shown. After cell lysis, an immunoprecipitation was conducted with anti-Shc polyclonal antibody. Western blotting using the monoclonal antiphosphotyrosine 4G10 was performed (pTyr immunoblot). The blot was stripped and reprobed with an anti-Shc polyclonal antibody (Shc immunoblot) or an anti-Grb2 MoAb (Grb2 immunoblot). Molecular mass standards are indicated. Ab, antibody.

Close modal

A time-course experiment was next performed to determine the kinetics of Shc activation in CTLL-EPO-R cells (Fig 2B). IL-2 rapidly induced Shc tyrosine phosphorylation in CTLL-EPO-R cells within 1 minute (Fig 2B, lanes 2 through 6) whereas 50 U/mL EPO failed to activate Shc phosphorylation at any time point for two independent CTLL-EPO-R subclones (Fig 2B, lanes 8 through 12 and 14). Other substrates, such as EPO-R and JAK2, demonstrated time- and concentration-dependent activation in CTLL-EPO-R cells.32 Similar amounts of Shc were immunoprecipitated in this experiment (Fig 2B, Shc Immunoblot). Again, Grb2 association with Shc was observed only upon IL-2–dependent Shc tyrosine phosphorylation (Fig 2B, Grb2 Immunoblot).

EPO activates the tyrosine phosphorylation of the EPO-R and the formation of EPO-R/ Grb2 complexes.Because EPO did not activate Shc in CTLL-EPO-R cells, we reasoned that if the Grb2/mSOS/Ras pathway was activated, it would be mediated by an Shc-independent pathway. For example, previous studies have shown that the Grb2 binds EGF-R directly and thereby activates the Ras pathway.44 CTLL-EPO-R cells were starved and stimulated with various cytokines, and cellular proteins were immunoprecipitated with either anti-Grb2 or anti-EPO-R antibodies (Fig 3). EPO activated the tyrosine phosphorylation of EPO-R (Fig 3, lane 10), which co-immunoprecipitated as a 72-kD phosphoprotein with an anti-Grb2 antibody (Fig 3, lane 5). The Shc signal (pp52 and pp46) is somewhat overexposed in this experiment, because a long exposure was required to observe other associated proteins. Multiple phosphoproteins associated with Grb2 upon IL-2 and IL-15 stimulation, including Shc, a pp80-kDa protein (possibly IL-2-R β) and pp64, pp97, and pp145. A 145-kD protein has been observed to associate with the phosphotyrosine binding domain (PTB) of Shc after fibroblast growth factor (FGF )45 stimulation and has recently been described as an SH2-domain inositol 5-phosphatase (SHIP).46-48 

Fig. 3.

EPO induces tyrosine phosphorylation and the formation of Grb2/EPO-R complexes. CTLL-EPO-R cells were depleted of cytokine for 8 hours and stimulated with no factor (lanes 1 and 6), 50 U of murine IL-2 per milliliter (lanes 2 and 7), 100 ng of murine IL-4 per milliliter (lanes 3 and 8), 100 ng of simian IL-15 per milliliter (lanes 4 and 9), or 50 U of human EPO per milliliter (lanes 5 and 10) for 10 minutes. After cell lysis, an immunoprecipitation was performed with either a Grb2 polyclonal antibody (lanes 1 through 5) or an anti-amino terminal EPO-R polyclonal antibody (lanes 6 through 10). Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with 4G10 monoclonal anti-phosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. The blot was then stripped and reprobed with a Grb2 polyclonal antibody. Molecular mass standards are indicated. Ab, antibody.

Fig. 3.

EPO induces tyrosine phosphorylation and the formation of Grb2/EPO-R complexes. CTLL-EPO-R cells were depleted of cytokine for 8 hours and stimulated with no factor (lanes 1 and 6), 50 U of murine IL-2 per milliliter (lanes 2 and 7), 100 ng of murine IL-4 per milliliter (lanes 3 and 8), 100 ng of simian IL-15 per milliliter (lanes 4 and 9), or 50 U of human EPO per milliliter (lanes 5 and 10) for 10 minutes. After cell lysis, an immunoprecipitation was performed with either a Grb2 polyclonal antibody (lanes 1 through 5) or an anti-amino terminal EPO-R polyclonal antibody (lanes 6 through 10). Immune complexes were resolved by SDS-PAGE and blotted to nitrocellulose. The immunoblot was probed with 4G10 monoclonal anti-phosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. The blot was then stripped and reprobed with a Grb2 polyclonal antibody. Molecular mass standards are indicated. Ab, antibody.

Close modal

EPO and IL-2 activate tyrosine phosphorylation of Shp2 and activate formation of Shp2/Grb2 complexes.Previous studies have shown an EPO-dependent physical interaction between Shp2 and Grb2 and between Shp2 and EPO-R.29 We reasoned, therefore, that the 64-kD protein activated by IL-2, IL-15, and EPO in CTLL-EPO-R cells might be Shp2. To test this hypothesis, we performed an anti-Grb2 immunoprecipitation (Fig 4). As observed in Fig 3, multiple phosphoproteins were shown to associate with Grb2 after cytokine stimulation. A 64-kD phosphoprotein was observed after IL-2 (Fig 4, lane 2), IL-15 (Fig 4, lane 4), or EPO (Fig 4, lane 5) stimulation of CTLL-EPO-R cells. This protein was shown to be Shp2 after stripping and reprobing with a monoclonal Shp2 antibody. IL-4 failed to induce tyrosine phosphorylation and association of Shp2 with Grb2, as previously described (Fig 4, lane 8).49 

Association of tyrosine phosphorylated 52- and 46-kD proteins paralleled the pattern of Shc activation shown in Fig 1 (Fig 4, pTyr immunoblot, lanes 2, 4, and 5). Subsequent stripping and reprobing the membrane showed that these proteins were in fact Shc (Fig 4, Shc immunoblot). IL-15, like its related cytokine, IL-2 also resulted in tyrosine phosphorylation and Grb2 association (Fig 4, lane 9). Tyrosine phosphorylated EPO-R was shown to co-immunoprecipitate as a 72- to 78-kD phosphoprotein (Fig 4, lane 5). A 145-kD Shc-associated protein, presumably SHIP,46-48 co-immunoprecipitated with Grb2 (Fig 4, lanes 2, 4, and 5). Equal amounts of Grb2 were immunoprecipitated in this experiment. These data show that, although EPO does not tyrosine phosphorylate Shc in CTLL-EPO-R cells, this cytokine activates Grb2/Shp2 complexes in these cells.

The activated EPO-R binds to the SH2 domains of Grb2 and Shp2.In CTLL-EPO-R cells, the tyrosine phosphorylated EPO-R co-immunoprecipitates with Grb2 and Shp2, but not with tyrosine phosphorylated Shc. GST fusion proteins containing the SH2 domains of Grb2, Shp2, or Shc were used to verify that the binding of Grb2 and Shp2 to the EPO-R is mediated by SH2 domain interactions (Fig 5). CTLL-EPO-R cells were stimulated in the presence of no added factor, IL-2, or EPO and incubated with various GST fusion proteins. Bound phosphoproteins were detected by antiphosphotyrosine immunoblotting. GST-SH2-Grb2 bound Shc (pp46 and pp52) only after IL-2 (Fig 5, lane 6), but not EPO (Fig 5, lane 10) stimulation, consistent with the immunoprecipitation data presented earlier. In addition, Shp2 (pp64) associated with GST-SH2-Grb2 after IL-2 (Fig 5, lane 6) or EPO (Fig 5, lane 10) stimulation. The EPO-R (pp72) was observed to associate with GST-SH2-Grb2 (Fig 5, lane 10) or GST-(N + C)-SH2-Shp2 (Fig 5, lane 11) after EPO stimulation. An additional, unidentified 60-kD phosphoprotein that is phosphorylated under conditions of cytokine deprivation is shown to associate with GST-(N + C)-SH2-Shp2 (Fig 5, lanes 3, 7, and 11). GST or GST-SH2-Shc fail to bind any phosphoproteins from CTLL-EPO-R cells.

Fig. 5.

The activated EPO-R binds directly to the SH2 domains of Grb2 and Shp2. CTLL-EPO-R cells were depleted of cytokine for 8 hours and stimulated with no factor (lanes 1 through 4, and 13), 50 U of murine IL-2 per milliliter (lanes 5 through 8, and 14) or 50 U of human EPO per milliliter (lanes 9 through 12, and 15) for 10 minutes. Lysates were incubated with 10 μg of GST (lanes 1, 5, and 9), GST-SH2-Grb2 (lanes 2, 6, and 10), GST-(N + C)-SH2-Shp2 (lanes 3, 7, and 11) or GST-SH2-Shc (lanes 4, 8, and 12). The immunoblot was probed with 4G10 monoclonal antiphosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. A diffuse, constitutively phosphorylated 60-kD phosphoprotein associates with GST-(N + C)-Shp2 (lanes 3, 7, and 11). Lysate controls from CTLL-EPO-R cells are illustrated in lanes 13 through 15. The migration of EPO-R, Shp2, and Shc were determined by stripping and reprobing the membrane as shown in Fig 4 (data not shown). Molecular mass standards are indicated. Ab, antibody.

Fig. 5.

The activated EPO-R binds directly to the SH2 domains of Grb2 and Shp2. CTLL-EPO-R cells were depleted of cytokine for 8 hours and stimulated with no factor (lanes 1 through 4, and 13), 50 U of murine IL-2 per milliliter (lanes 5 through 8, and 14) or 50 U of human EPO per milliliter (lanes 9 through 12, and 15) for 10 minutes. Lysates were incubated with 10 μg of GST (lanes 1, 5, and 9), GST-SH2-Grb2 (lanes 2, 6, and 10), GST-(N + C)-SH2-Shp2 (lanes 3, 7, and 11) or GST-SH2-Shc (lanes 4, 8, and 12). The immunoblot was probed with 4G10 monoclonal antiphosphotyrosine antibody followed by HRP-sheep anti-mouse IgG. A diffuse, constitutively phosphorylated 60-kD phosphoprotein associates with GST-(N + C)-Shp2 (lanes 3, 7, and 11). Lysate controls from CTLL-EPO-R cells are illustrated in lanes 13 through 15. The migration of EPO-R, Shp2, and Shc were determined by stripping and reprobing the membrane as shown in Fig 4 (data not shown). Molecular mass standards are indicated. Ab, antibody.

Close modal

EPO, IL-2, and IL-15 activate the Raf1 and MAP kinase pathway in CTLL-EPO-R cells.Other investigators have shown that effectors downstream of Ras including Raf150 and MAP kinase20 51 display EPO-dependent activation in a number of hematopoietic cell lines. To demonstrate the activation of the Ras pathway in CTLL-EPO-R cells, we analyzed Raf1 (Fig 6) and ERK2 activation (Fig 7).

Fig. 6.

IL-2, IL-15, and EPO activate Raf1-1 in CTLL-EPO-R cells. CTLL-EPO-R cells were depleted of cytokine for 8 hours in RPMI-1 mg/mL bovine serum albumin (BSA). Stimulations were conducted with no added cytokine (lane 1), 50 U of human EPO per mL (lane 2), 50 U of murine IL-2 per milliliter (lane 3), 100 ng of murine IL-4 per milliliter (lane 4), or 100 ng of simian IL-15 per milliliter (lane 5). After cell lysis, an immunoprecipitation was performed using an anti-Raf1 antibody, followed by an in vitro kinase reaction using MEK1 as an exogenous substrate. Samples were resolved by SDS-PAGE, transferred to nitrocellulose, and then exposed to film.

Fig. 6.

IL-2, IL-15, and EPO activate Raf1-1 in CTLL-EPO-R cells. CTLL-EPO-R cells were depleted of cytokine for 8 hours in RPMI-1 mg/mL bovine serum albumin (BSA). Stimulations were conducted with no added cytokine (lane 1), 50 U of human EPO per mL (lane 2), 50 U of murine IL-2 per milliliter (lane 3), 100 ng of murine IL-4 per milliliter (lane 4), or 100 ng of simian IL-15 per milliliter (lane 5). After cell lysis, an immunoprecipitation was performed using an anti-Raf1 antibody, followed by an in vitro kinase reaction using MEK1 as an exogenous substrate. Samples were resolved by SDS-PAGE, transferred to nitrocellulose, and then exposed to film.

Close modal
Fig. 7.

IL-2, IL-15, and EPO activate ERK2 in CTLL-EPO-R cells. CTLL-EPO-R cells were depleted of cytokine for 8 hours in RPMI-1 mg/mL BSA. Stimulations were conducted with no added cytokine (lane 1), 50 U of murine IL-2 per milliliter (lane 2), 100 ng of murine IL-4 per milliliter (lane 3), or 100 ng of simian IL-15 per milliliter (lane 4) or 50 U of human EPO per mL (lane 5). After cell lysis, an immunoprecipitation was performed using an anti-ERK2 antibody, followed by an in vitro kinase reaction using myelin basic protein (MBP) as an exogenous substrate. Samples were resolved by SDS-PAGE, transferred to nitrocellulose and then exposed to film.

Fig. 7.

IL-2, IL-15, and EPO activate ERK2 in CTLL-EPO-R cells. CTLL-EPO-R cells were depleted of cytokine for 8 hours in RPMI-1 mg/mL BSA. Stimulations were conducted with no added cytokine (lane 1), 50 U of murine IL-2 per milliliter (lane 2), 100 ng of murine IL-4 per milliliter (lane 3), or 100 ng of simian IL-15 per milliliter (lane 4) or 50 U of human EPO per mL (lane 5). After cell lysis, an immunoprecipitation was performed using an anti-ERK2 antibody, followed by an in vitro kinase reaction using myelin basic protein (MBP) as an exogenous substrate. Samples were resolved by SDS-PAGE, transferred to nitrocellulose and then exposed to film.

Close modal

CTLL-EPO-R cells were depleted of cytokine for 8 hours in serum-free conditions before stimulation with the indicated cytokines. Raf1 was then immunoprecipitated from the lysates and in vitro kinase reactions were performed in the presence of kinase inactive purified MEK1 as an exogenous substrate. IL-2, IL-15, and EPO all led to an increase in MEK1 phosphorylation (Fig 6). The amount of IL-4–dependent Raf1 activation was increased over background, but less than that observed with other cytokines in this experiment. EPO stimulation resulted in a threefold stimulation of Rafl activity, similar to IL-2 and IL-15 as monitored by phosphorimager detection (data not shown). These data are representative of three independent experiments. Equal amounts of Raf1 were immunoprecipitated in this experiment as revealed by probing the membrane with a Raf1 antibody (data not shown).

Next, the activation of ERK1 and ERK2 was examined (Fig 7). Lysates from CTLL-EPO-R–stimulated cells were immunoprecipitated with anti-ERK1 or anti-ERK2 peptide-specific antibodies. An in vitro kinase reaction was then performed using myelin basic protein as an exogenous substrate. IL-2, IL-15, and EPO all activated ERK2 as detected by enhanced phosphorylation of MBP (Fig 7). The level of IL-4–dependent MBP phosphorylation was enhanced over background. EPO, like IL-2 and IL-15, activated MBP phosphorylation twofold as determined by phosphorimager detection (data not shown). These data were found to be reproducible in three independent experiments. Similarly, IL-2, IL-15, and EPO stimulations resulted in tyrosine phosphorylation of ERK2 in immunoprecipitation/Western blotting experiments (data not shown). ERK1 kinase activity was not enhanced by any of the cytokines in CTLL-EPO-R cells, although ERK1 is expressed in CTLL-EPO-R cells (data not shown).

Previous studies have shown that Shc is rapidly tyrosine phosphorylated in response to EPO,18-21,41 IL-2,33-36 IL-3,19,21,41,52-54 IL-5,53,54 granulocyte-macrophage colony-stimulating factor (GM-CSF ),52-54 growth hormone,55 and thrombopoietin.56 57 In the present study we have demonstrated that EPO activates Shc in some, but not all, EPO-dependent cell lines.

CTLL-EPO-R cells display EPO-dependent proliferation31,32 and activation of JAK232,58 and STAT558 (Barber DL, unpublished observation). Here we show that EPO stimulates the tyrosine phosphorylation of the EPO-R and Shp2 which both can bind to the SH2 adaptor protein Grb2. Stimulation with either IL-2 or IL-15 results in dose- and time-dependent Shc tyrosine phosphorylation in CTLL-EPO-R cells. However, EPO failed to stimulate Shc tyrosine phosphorylation in any of these experiments.

Why EPO fails to activate Shc tyrosine phosphorylation in CTLL-EPO-R cells is not clear. CTLL-EPO-R have similar EPO-R receptor number, affinity, and EPO dose-dependent growth characteristics when compared to other EPO-dependent cell lines.32 The EPO-R may be differentially tyrosine phosphorylated in CTLL-EPO-R cells. Therefore, Shc may be unable to dock to the EPO-R and as a result is not tyrosine phosphorylated. Conversely, Shc may associate with the tyrosine-phosphorylated EPO-R but is not itself tyrosine phosphorylated. However, EPO-R failed to associate with Shc in CTLL-EPO-R (data not shown). JAK2 can phosphorylate Shc when analyzed by in vitro kinase reactions using lysates prepared with Brij 96.21 EPO activates JAK2 in CTLL-EPO-R32; therefore, the block in Shc activation does not reside in aberrant Janus kinase activation. It has been shown that IL-2 activates the lck59-61  and Syk protein tyrosine kinases.62 However, Syk is not expressed in CTLL cells (data not shown). lck phosphorylates Shc in similar in vitro experiments.63 It is unknown which, if any, src family kinases are activated by EPO. Perhaps the failure of EPO to activate Shc in CTLL-EPO-R cells results from the inability of EPO-R to activate lck.

Several reports describe EPO-R expression in CTLL cells. One study indicated that EPO-R failed to generate an EPO-dependent response in CTLL cells.64 Overexpression of K-Ras generated an EPO-dependent growth response and was shown to be correlated with the IL-2 or EPO-dependent activation of 130- and 160-kD phosphoproteins.65 Another study demonstrated EPO-dependent growth of CTLL-EPO-R cells after a latent period of 4 to 15 days.66 We have characterized the growth and proliferative capacity of CTLL-EPO-R cells in earlier studies.31,32 Multiple reports have indicated that JAK2,32,67 STAT5,58 68 and EPO-R (this study) are all tyrosine phosphorylated, irrespective of EPO-growth dependency. The inability of certain CTLL-EPO-R subclones to proliferate in EPO therefore does not result from aberrant JAK-STAT signaling.

Despite prominent EPO-dependent Shc activation in Ba/F3-EPO-R, DA-3-EPO-R, and HCD-57, Shc failed to co-immunoprecipitate with the EPO-R from Triton X-100 lysates. Shc may bind to the EPO-R via its amino terminal phosphotyrosine binding domain (PTB),45,69 or the carboxy terminal SH2 domain. However, the EPO-R cytoplasmic tail does not contain any potential NPXY binding sites for PTB domains.13,70-72 The ability of the Shc SH2 domain to bind directly to the EPO-R under physiologically relevant conditions remains to be established. Alternatively, Shc could associate indirectly with the EPO-R through a bridging molecule such as SHIP, an inositol 5-phosphatase recently identified.46-48 The association between Shc and EPO-R in MO-7-EPO-R may result from overexpression of EPO-R in this cell line.18 

Two other recent studies illustrate that cytokine-dependent Shc activation is not required for mitogenesis. Shc associates with the IL-3-R βc chain at Y577.73 Mutation of this critical tyrosine does not adversely affect GM-CSF-R–dependent proliferation, JAK-STAT activation, or Raf1 activation.73 Mutation of Y388 in the IL-2-R β-chain prevents association of Shc with the IL-2-R β.74 Furthermore, Shc was not tyrosine phosphorylated and Shc phosphorylation was not required for IL-2–dependent proliferation.74 The association of Shc with the IL-3-R βc75 or IL-2-R β-chain76 is mediated by the phosphotyrosine binding domain of Shc.

The Grb2 SH2 domain binds to tyrosine phosphorylated proteins containing the motif YXN.77 A number of the proteins examined in these experiments contain this motif. Shc phosphorylated at Y317 (YVNV) binds Grb2.15 Shp2 contains two such motifs at Y542 (YTNI) and Y580 (YENV).28 In addition, the EPO-R has a consensus Grb2 binding motif at Y463 (YENS).78 It is unknown if the EPO-R is tyrosine phosphorylated at this position. Therefore, Grb2 may bind directly to two or more substrates in these experiments.

An activated growth factor receptor may activate the Ras/Raf1/MAP kinase pathway via multiple alternative mechanisms. The tyrosine kinase receptor, PDGF-R, can activate Ras via Grb2 direct, Shc/Grb2, or SH-PTP-2/Grb2 mechanisms.26-28 Regarding EPO-dependent Ras activation, in Ba/F3-EPO-R, DA-3-EPO-R, and HCD-57 cells, all three mechanisms appear to be intact (data not shown). However, in CTLL-EPO-R, Grb2 associates with the EPO-R directly or through binding to Shp2, but without Shc activation. The level of Shp2 tyrosine phosphorylation varies among the cell lines examined in this study (data not shown). This implies that Shp2 may have a varying role in Grb2 recruitment.

EPO, IL-2, and IL-15 activated Raf1 (2.5- to 3.0-fold) and ERK2 (1.7- to 1.8-fold) kinase activity to a similar degree, as reported earlier for EPO.20,51 However, IL-4 displayed intermediate activation of Raf1 (1.8-fold) and ERK2 (1.2-fold) when compared with unstimulated controls. CTLL cells fail to proliferate in IL-4, but JAK1 and JAK3 are activated by this cytokine.32 Previous studies had failed to observe IL-4–dependent activation of the Ras signaling cascade.79 80 

The biologic importance of Ras/Raf1/MAP kinase activation by the cytoplasmic tail of the EPO-R remains unknown. While the carboxy-terminus of the EPO-R activates this pathway and correlates with c-fos induction,81 this region of the carboxy terminus can be truncated without a loss of mitogenic signal in transfected Ba/F3 cells.37,82 When a truncated EPO-R lacking 108 amino acids is expressed in 32D cells, EPO-dependent Shc activation was not observed, despite normal JAK2 activation.20 However, in FDCP-1 transfectants, a truncated EPO-R lacking 154 amino acids displayed both Shc and JAK2 tyrosine phosphorylation and mitogenesis.21 The membrane proximal region of the EPO-R is required for mitogenesis and JAK2 activation.21 83 The differences observed in Shc activation in these cell lines suggest either multiple mechanisms of EPO-R–dependent Grb2 recruitment exist, or that EPO-dependent activation of additional tyrosine kinases occurs in selected hematopoietic cell lines. Although activation of the Ras/Raf1/MAP kinase may not be required for growth of immortalized cell lines, like 32D, it may be essential for growth of primary hematopoietic cells.

We thank David Cosman (Immunex Corp, Seattle, WA) for the gift of IL-15, Jim Griffin for GST-SH2-Shc, and Ben Neel for GST-SH2-Grb2 and GST-(N + C)-SH2-Shp2. We appreciate helpful comments on the manuscript from Martin Carroll, Cheryl Miller, Sonya Penfold, and Kodimangalam Ravichandran. We thank Anton Bennett, Ben Neel, Kodimangalam Ravichandran, Joanne Pratt, and members of the D'Andrea laboratory for helpful discussions throughout this work.

Supported by a grant from National Institutes of Health (Award RO1 DK 43889-01) (A.D.D.). D.L.B. was supported by Alberta Heritage Foundation for Medical Research and the Leukemia Society of America. A.D.D. is a Scholar of the Leukemia Society of America.

Address reprint requests to Alan D. D'Andrea, MD, Dana-Farber Cancer Institute, Pediatric Oncology, 44 Binney St, Boston, MA 02115.

1
Sato
N
Sakamaki
K
Terada
N
Arai
K-I
Miyajima
A
Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common β subunit responsible for different signaling.
EMBO J
12
1993
4181
2
Quelle
FW
Sato
N
Witthuhn
BA
Inhorn
RC
Eder
M
Miyajima
A
Friffin
JD
Ihle
JN
Jak2 associates with the βc chain of the receptor for granulocyte macrophage colony-stimulating factor, and its activation requires the membrane-proximal region.
Mol Cell Biol
14
1994
4335
3
Sakamaki
K
Miyajima
I
Kitamura
T
Miyajima
A
Critical cytoplasmic domains of the common β subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation.
EMBO J
11
1992
3541
4
Lowenstein
EJ
Daly
RJ
Batzer
AG
Li
W
Margolis
B
Lammers
R
Ullrich
A
Skolnik
EY
Bar
SD
Schlessinger
J
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.
Cell
70
1992
431
5
Egan
SE
Giddings
BW
Brooks
MW
Buday
L
Sizeland
AM
Weinberg
RA
Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation.
Nature
363
1993
45
6
Rozakis-Adcock
M
Fernley
R
Wade
J
Pawson
T
Bowtell
D
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1.
Nature
363
1993
83
7
Li
N
Batzer
A
Daly
R
Yajnik
V
Skolnik
E
Chardin
P
Bar-Sagi
D
Margolis
B
Schlessinger
J
Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling.
Nature
363
1993
85
8
Gale
NW
Kaplan
S
Lowenstein
EJ
Schlessinger
J
Bar-Sagi
D
Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras.
Nature
363
1993
88
9
Buday
L
Downward
J
Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.
Cell
73
1993
611
10
Baltensperger
K
Kozma
LM
Cherniack
AD
Klarlund
JK
Chawla
A
Banerjee
U
Czech
MP
Binding of the Ras activator Son of Sevenless to insulin receptor substrate-1 signaling complexes.
Science
260
1993
1950
11
Skolnik
EY
Batzer
A
Li
N
Lee
CH
Lowenstein
E
Mohammadi
M
Margolis
B
Schlessinger
J
The function of GRB2 in linking the insulin receptor to Ras signaling pathways.
Science
260
1993
1953
12
Pelicci
G
Lanfrancone
L
Grignani
F
McGlade
J
Cavallo
F
Forni
G
Nicoletti
I
Grignani
F
Pawson
T
Pelicci
PG
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.
Cell
70
1992
93
13
vanderGeer
P
Pawson
T
The PTB domain: A new protein module implicated in signal transduction.
Trends Biochem Sci
20
1995
277
14
Pawson
T
Protein modules and signalling networks.
Nature
373
1995
573
15
Salcini
AE
McGlade
J
Pelicci
G
Nicoletti
I
Pawson
T
Pelicci
PG
Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins.
Oncogene
9
1994
2827
16
Stephens
RM
Loeb
DM
Copeland
TD
Pawson
T
Greene
LA
Kaplan
DR
Trk receptors use redundant signal transduction pathways involving SHC and PLC-g1 to mediate NGF responses.
Neuron
12
1994
691
17
Obermeier
A
Bradshaw
RA
Seedorf
K
Choidas
A
Schlessinger
J
Ullrich
A
Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLCg .
EMBO J
13
1994
1585
18
Damen
JE
Liu
L
Cutler
RL
Krystal
G
Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein.
Blood
82
1993
2296
19
Cutler
RL
Liu
L
Damen
JE
Krystal
G
Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells.
J Biol Chem
268
1993
21463
20
Miura
Y
Miura
O
Ihle
JN
Aoki
N
Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.
J Biol Chem
269
1994
29962
21
He
TC
Jiang
N
Zhuang
H
Wojchowski
DM
Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway.
J Biol Chem
270
1995
11055
22
Freeman
RM
Plutzky
J
Neel
BG
Identification of a human src homology 2-containing protein-tyrosine phosphatase: A putative homolog of Drosophila corkscrew.
Proc Natl Acad Sci USA
89
1992
11239
23
Adachi
M
Sekiya
M
Miyachi
T
Matsuno
K
Hinoda
Y
Imai
K
Yachi
A
Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3 with sequence similarity to the src-homology region 2.
FEBS Lett
314
1992
335
24
Vogel
W
Lammers
R
Houng
J
Ullrich
A
Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation.
Science
259
1993
1611
25
Ahmad
S
Banville
D
Zhao
Z
Fischer
EH
Shen
S-H
A widely expressed human protein-tyrosine phosphatase containg src homology 2 domains.
Proc Natl Acad Sci USA
90
1993
2197
26
Kazlauskas
A
Feng
GS
Pawson
T
Valius
M
The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp.
Proc Natl Acad Sci USA
90
1993
6939
27
Li
W
Nishimura
R
Kashishian
A
Batzer
AG
Kim
WJ
Cooper
JA
Schlessinger
J
A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase.
Mol Cell Biol
14
1994
509
28
Bennett
AM
Tang
TL
Sugimoto
S
Walsh
CT
Neel
BG
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.
Proc Natl Acad Sci USA
91
1994
7335
29
Tauchi
T
Feng
GS
Shen
R
Hoatlin
M
Bagby
GJ
Kabat
D
Lu
L
Broxmeyer
HE
Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways.
J Biol Chem
270
1995
5631
30
Tauchi
T
Damen
JE
Toyama
K
Feng
G-S
Broxmeyer
HE
Krystal
G
Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis.
Blood
87
1996
4495
31
Showers
MO
Moreau
J-F
Linnekin
D
Druker
B
D'Andrea
AD
Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation.
Blood
80
1992
3070
32
Barber
DL
D'Andrea
AD
Erythropoietin and Interleukin-2 activate distinct JAK kinase family members.
Mol Cell Biol
14
1994
6506
33
Burns
LA
Karnitz
LM
Sutor
SL
Abraham
RT
Interleukin-2-induced tyrosine phosphorylation of p52shc in T lymphocytes.
J Biol Chem
268
1993
17659
34
Ravichandran
KS
Burakoff
SJ
The adapter protein Shc interacts with the interleukin-2 (IL-2) receptor upon IL-2 stimulation.
J Biol Chem
269
1994
1599
35
Zhu
X
Suen
KL
Barbacid
M
Bolen
JB
Fargnoli
J
Interleukin-2-induced tyrosine phosphorylation of Shc proteins correlates with factor-dependent T cell proliferation.
J Biol Chem
269
1994
5518
36
Dorsch
M
Hock
H
Diamantstein
T
Gene transfer of the interleukin (IL)-2 receptor beta chain into an IL-7-dependent pre-B cell line permits IL-2-driven proliferation: Tyrosine phosphorylation of Shc is induced by IL-2 but not IL-7.
Eur J Immunol
24
1994
2049
37
D'Andrea
AD
Yoshimura
A
Youssoufian
H
Zon
LI
Koo
J-W
Lodish
HF
The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains.
Mol Cell Biol
11
1991
1980
38
Miura
O
D'Andrea
AD
Kabat
D
Ihle
JN
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis.
Mol Cell Biol
11
1991
4895
39
Gillis
S
Smith
KA
Long-term culture of tumor-specific cytolytic T-cells.
Nature
268
1977
154
40
Ruscetti
SK
Janesch
NJ
Chakroborti
A
Sawyer
ST
Hankins
WD
Friend spleen focus-forming virus induces factor independence in an erythropoietin-dependent erythroleukemia cell line.
J Virol
63
1990
1057
41
Barber
DL
DeMartino
JC
Showers
MO
D'Andrea
AD
A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation.
Mol Cell Biol
14
1994
2257
42
Frangioni
JV
Neel
BG
Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins.
Anal Biochem
210
1992
179
43
Fu
H
Xia
K
Pallas
DC
Cui
C
Conroy
K
Narsimhan
RP
Mamon
H
Collier
RJ
Roberts
TM
Interaction of the protein kinase Raf-1 with 14-3-3 proteins.
Science
266
1994
126
44
Batzer
AG
Rotin
D
Urena
JM
Skolnik
EY
Schlessinger
J
Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.
Mol Cell Biol
14
1994
5192
45
Kavanaugh
WM
Williams
LT
An alternative to SH2 domains for binding tyrosine-phosphorylated proteins.
Science
266
1994
1862
46
Damen
JE
Liu
L
Rosten
P
Humphries
RK
Jefferson
AB
Majerus
PW
Krystal
G
The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.
Proc Natl Acad Sci USA
93
1996
1689
47
Kavanaugh
WM
Pot
DA
Chin
SM
Deuter-Reinhard
M
Jefferson
AB
Norris
FA
Masiarz
FR
Cousens
LS
Majerus
PW
Williams
LT
Multiple forms of an inositol polyphospate 5-phosphatase form signaling complexes with Shc and Grb2.
Curr Biol
6
1996
438
48
Lioubin
MN
Algate
PA
Tsai
S
Carlberg
K
Aebersold
R
Rohrschneider
LR
p150Ship, a signal transduction molecule with inositol polyphospate-5-phosphatase activity.
Genes Dev
10
1996
1084
49
Welham
MJ
Dechert
U
Leslie
KB
Jirik
F
Schrader
JW
Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3′- kinase.
J Biol Chem
269
1994
23764
50
Carroll
MP
Spivak
JL
McMahon
M
Weich
M
Rapp
UR
May
WS
Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation.
J Biol Chem
266
1991
14964
51
Todokoro
K
Sugiyama
M
Nishia
E
Nakaya
K
Activation of mitogen-activated protein kinase cascade through erythropoietin receptor.
Biochem Biophys Res Commun
203
1994
1912
52
Matsuguchi
T
Salgia
R
Hallek
M
Eder
M
Druker
B
Ernst
TJ
Griffin
JD
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
J Biol Chem
269
1994
5016
53
Dorsch
M
Hock
H
Diamantstein
T
Tyrosine phosphorylation of Shc is induced by IL-3, IL-5 and GM-CSF.
Biochem Biophys Res Commun
200
1994
562
54
Lanfrancone
L
Pelicci
G
Brizzi
MF
Arouica
MG
Casciari
C
Giuli
S
Pegoraro
L
Pawson
T
Pelicci
PG
Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SoS and Grb2/p140 complexes to the beta receptor subunit.
Oncogene
10
1995
907
55
VanderKuur
J
Allevato
G
Billestrup
N
Norstedt
G
Carter
SC
Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2.
J Biol Chem
270
1995
7587
56
Drachman
JG
Griffin
JD
Kaushansky
K
The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.
J Biol Chem
270
1995
4979
57
Gurney
AL
Wong
SC
Henzel
WJ
deSauvage
FJ
Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK- STAT signal transduction pathway and Shc phosphorylation.
Proc Natl Acad Sci USA
92
1995
5292
58
Wakao
H
Harada
N
Kitamura
T
Mui
AL-F
Miyajima
A
Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways.
EMBO J
14
1995
2527
59
Hatakeyama
M
Kono
T
Kobayashi
N
Kawahara
A
Levin
SD
Perlmutter
RM
Taniguchi
T
Interaction of the IL-2 receptor with the src-family kinase p56lck: Identification of a novel intermolecular association.
Science
252
1991
1523
60
Horak
ID
Gress
RE
Lucas
PJ
Horak
EM
Waldmann
TA
Bolen
JB
T lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.
Proc Natl Acad Sci USA
88
1991
1996
61
Minami
Y
Kono
T
Yamada
K
Kobayashi
N
Kawahara
A
Perlmutter
RM
Taniguchi
T
Association of p56lck with IL-2 receptor β chain is critical for the IL-2-induced activation of p56lck.
EMBO J
12
1993
759
62
Minami
Y
Nakagawa
Y
Kawahara
A
Miyazaki
T
Sada
K
Yamamura
H
Taniguchi
T
Protein tyrosine kinase Syk is associated with and activated by the IL-2 receptor: Possible link with the c-myc induction pathway.
Immunity
2
1995
89
63
Ravichandran
KS
Lorenz
U
Shoelson
SE
Burakoff
SJ
Interaction of Shc with Grb2 regulates association of Grb2 with mSOS.
Mol Cell Biol
15
1995
593
64
Yamamura
Y
Kageyama
U
Matuzaki
T
Noda
M
Ikawa
Y
Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor.
EMBO J
11
1992
4909
65
Yamamura
Y
Noda
M
Ikawa
Y
Activated Ki-Ras complements erythropoietin signaling in CTLL-2 cells, inducing tyrosine phosphorylation of a 160 kDa protein.
Proc Natl Acad Sci USA
91
1994
8866
66
Sakamaki K, Wang H-M, Miyajima I, Kitamura T, Todokoro K, Harada N, Miyajima A: Ligand-dependent activation of chimeric receptors with the cytoplasmic domain of the Interluekin-3 receptor β subunit (βIL3). J Biol Chem. 268:15833, 1993
67
Witthuhn
BA
Silvennoinen
O
Miura
O
Lai
KS
Cwik
C
Liu
ET
Ihle
JN
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells.
Nature
370
1994
153
68
Quelle
FW
Wang
D
Nosaka
T
Thierfelder
WE
Stravopodis
D
Weinstein
Y
Ihle
JN
Erythropoietin induces activation of Stat5 through association with specific tyrosine on the receptor that are not required for a mitogenic response.
Mol Cell Biol
16
1996
1622
69
Blaikie
P
Immanuel
D
Wu
J
Li
N
Yajnik
V
Margolis
B
A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors..
J Biol Chem
269
1994
32031
70
Kavanaugh
WM
Turck
CW
Williams
LT
PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine.
Science
268
1995
1177
71
Songyang
Z
Margolis
B
Chaudhuri
M
Shoelson
SE
Cantley
LC
The phosphotyrosine interaction domain of SHC recognizes tyrosine-phosphorylated NPXY motif.
J Biol Chem
270
1995
14863
72
Trub
T
Choi
WE
Wolf
G
Ottinger
E
Chen
YJ
Weiss
M
Shoelson
SE
Specificity of the PTB domain of Shc of β turn-forming pentapeptide motifs amino-terminal to phosphotyrosine.
J Biol Chem
270
1995
18205
73
Durstin
M
Inhorn
RC
Griffin
JD
Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines.
J Immunol
157
1996
535
74
Evans
GA
Goldsmith
MA
Johnston
JA
Xu
W
Weiler
SR
Erwin
R
Howard
OMZ
Abraham
RT
O'Shea
JJ
Greene
W
Farrar
WL
Analysis of interleukin-2-dependent signal transduction through the Shc/Grb2 adapter pathway. Interleukin-2-dependent mitogenesis does not require Shc phosphorylation or receptor association.
J Biol Chem
270
1995
28858
75
Pratt
JC
Weiss
M
Sieff
CA
Shoelson
SE
Burakoff
SJ
Ravichandran
KS
Evidence for a physical association between the Shc-PTB domain and the βc chain of the granulocyte-macrophage colony stimulating factor receptor.
J Biol Chem
271
1996
12137
76
Ravichandran
KS
Igras
V
Shoelson
SE
Fesik
SW
Burakoff
SJ
Evidence for a role for the PTB domain of Shc in interleukin-2 signaling.
Proc Natl Acad Sci USA
93
1996
5275
77
Songyang
Z
Shoelson
SE
McGlade
J
Olivier
P
Pawson
T
Bustelo
XR
Barbacid
M
Sabe
H
Hanafusa
H
Yi
T
Ren
R
Baltimore
D
Ratnofsky
S
Feldman
RA
Cantley
LC
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.
Mol Cell Biol
14
1994
2777
78
D'Andrea
AD
Lodish
HF
Wong
GG
Expression cloning of the murine erythropoietin receptor.
Cell
57
1989
277
79
Satoh
T
Nakafuku
M
Mayajima
S
Kaziro
Y
Involvement of ras p21 protein in signal-transduction from the interleukin 2, interleukin 3 and granulocyte/macrophage colony-stimulating factor, but not from interleukin-4.
Proc Natl Acad Sci USA
88
1991
3314
80
Welham
MJ
Duronio
V
Leslie
KB
Bowtell
D
Schrader
JW
Multiple hemopoietins, with the exception of interleukin-4, induce modification of Shc and mSos1, but not their translocation.
J Biol Chem
269
1994
21165
81
Miura
O
Cleveland
JL
Ihle
JN
Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors.
Mol Cell Biol
13
1993
1788
82
Gobert
S
Porteu
F
Pallu
S
Muller
O
Sabbah
M
Dusanter-Fourt
I
Courtois
G
Lacombe
C
Gisselbrecht
S
Mayeux
P
Tyrosine phosphorylation of the erythropoietin receptor: Role for differentiation and mitogenic signal transduction.
Blood
86
1995
598
83
Witthuhn
BA
Quelle
FW
Silvennoinen
O
Yi
T
Tang
B
Miura
O
Ihle
JN
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
Cell
74
1993
227
Sign in via your Institution